Journal of Allergy and Hypersensitivity Diseases最新文献

{"title":"Egg allergy: An obstacle to childhood vaccination. Recommendations for vaccination practices","authors":"Juliette Caron ,&nbsp;Alexia Guilbert ,&nbsp;Hugo Devooght ,&nbsp;Patricia Rannaud-Bartaire ,&nbsp;Anne Herman ,&nbsp;Florence Libon ,&nbsp;Christine Delebarre-Sauvage","doi":"10.1016/j.jahd.2025.100045","DOIUrl":"10.1016/j.jahd.2025.100045","url":null,"abstract":"<div><h3>Introduction</h3><div>This study explores the current vaccination practices of French general practitioners regarding children with egg allergy.</div></div><div><h3>Methods</h3><div>An observational survey was carried out in the North of France using a questionnaire intended for volunteer general practioners.</div></div><div><h3>Results</h3><div>Among 93 general practitioners surveyed, the majority (88.9 %) considered egg allergy to be problematic in case of a vaccination. The three most problematic vaccines were those against influenza, yellow fever and measles, mumps and rubella.</div></div><div><h3>Discussion</h3><div>Egg allergy may represent an obstacle to children vaccination. We submit recommendations for vaccination practices.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"7 ","pages":"Article 100045"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of an allergic patients database for determining pollen-induced asthma prevalence rates","authors":"Alina Gherasim ,&nbsp;Thibaut Riff ,&nbsp;Frank Dietsch ,&nbsp;Florian Odul ,&nbsp;Nathalie Domis ,&nbsp;Hubert Mechin ,&nbsp;Frederic de Blay","doi":"10.1016/j.jahd.2025.100043","DOIUrl":"10.1016/j.jahd.2025.100043","url":null,"abstract":"<div><h3>Background</h3><div>The prevalence of allergy to pollen is increasing. Alyatec is a clinical trial center running an environmental exposure chamber and collects medical information on allergic patients.</div></div><div><h3>Objective</h3><div>The purpose of this study was to assess the frequency of allergic respiratory diseases and their comorbidities, and to identify pollen-related asthma in allergic patients, using the Alyatec database.</div></div><div><h3>Method</h3><div>Alyatec database counts 2079 allergic patients included with skin prick testing for common aeroallergens, medical and allergy history. Patients gave their consent to be included in this General Data Protection Regulation (GDPR)-compliant database.</div></div><div><h3>Results</h3><div>The mean age was 35.3 years, with 60 % women. The majority lived in the Strasbourg area. Asthma was found in 71 %, 99 % had rhinitis, 90 % had conjunctivitis, and 71 % had both, asthma and rhinitis. They were polysensitized: 64 % to house dust mites, 66 % to cats, 57 % to birch pollen, and 69 % to grass pollen; 77 % had mild asthma with 71 % controlled asthma. Among patients sensitized to pollen, 46 % of those with a birch pollen allergy and 43 % of those with a grass pollen allergy were asthmatic. Similar results were obtained in patients with allergic rhinitis without asthma caused by birch and grass pollen during airborne allergen exposures in Alyatec environmental exposure chamber: early asthma responses were observed in 53 % of birch pollen-allergic patients and 50 % of grass pollen-allergic patients.</div></div><div><h3>Conclusion</h3><div>Asthma to birch and grass pollen appears to be more common than previously described and should be better considered in future allergen immunotherapy trials.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"6 ","pages":"Article 100043"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drago®: An innovative mobile application to improve adherence and complience of house dust mite allergen immunotherapy","authors":"Luciana Kase Tanno ,&nbsp;Pham Thao Van Luong ,&nbsp;Éric Fromentin ,&nbsp;Édouard Sève ,&nbsp;Mickaël Poulequin ,&nbsp;Hoai-Bich Trinh ,&nbsp;Julien Cottet ,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2025.100041","DOIUrl":"10.1016/j.jahd.2025.100041","url":null,"abstract":"<div><h3>Background</h3><div>House dust mite (HDM) allergens constitute the most frequent cause of persistent allergic rhinitis and asthma. Allergen immunotherapy (AIT) is the only disease-modifying treatment for patients suffering from IgE-mediated allergic conditions. The Drago® application is a free application to optimize the use of AIT through education modules, timing track and implementation of adherence based on games and avatar evolution.</div></div><div><h3>Methods</h3><div>Consecutive patients were offered to voluntarily use the application simultaneously to their AIT. We evaluated data related to patients’ adherence to HDM AIT over 3 years. Data generated were anonymized and stored following the French regulations. Compliance referred to the ratio of the number of doses taken by the patient to the duration of APP use by the patient, expressed as a percentage. Adherence was measured by comparing measured persistence (duration between the last date of the application use and starting date of treatment) with ideally expected persistence. Quality of life (QoL), Allergic Rhinitis Control Test (ARCT) and Global Initiative for Asthma (GINA) control scores have been evaluated at three different time points: the first, second, and third years of application use).</div></div><div><h3>Results</h3><div>From overall 4,906 users after 3 years of launch, 2,490 (50.7 %) were undergoing HDM AIT, with 244,200 numbers of accesses to the Drago® application. Mean age of users was 21 years, most of patients were children (74.6 %). Number of accesses overtime by children were proportionally higher than by adults and adolescents. Over 80 % percent of patients used the application from 7:00 to 10:00 AM (27.2 %) and from 18:00 to 21:00 PM (53.7 %). At year 3, mean rate of compliance over a period of three years was 45 % (confidence interval [CI]: 44.1 %–46.1 %), mean persistence was estimated in 327 days (CI: 315–337 days), with 76 % of mean percentage adherence (CI: 74.9 %–76.7 %). Persistence and adherence were significantly higher in children, but compliance was more significant in adults. We observed significant improvements in the mean ARCT, and QoL scores across three time points (first year, second year and third year).</div></div><div><h3>Conclusion</h3><div>Positive impact on adherence, persistence and burden of respiratory diseases were observed in patients using Drago® application and undergoing HDM AIT, in particular in childhood. Consolidating the presented data with the English version of Drago® application will soon be available.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"6 ","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144084274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy hypersensitivity: Current insights and novel desensitization strategies","authors":"Gordon K.H. Chu ,&nbsp;Andy K.C. Kan ,&nbsp;James K.Y. Hooi ,&nbsp;Hye-Ryun Kang ,&nbsp;Philip H. Li","doi":"10.1016/j.jahd.2025.100042","DOIUrl":"10.1016/j.jahd.2025.100042","url":null,"abstract":"<div><div>This review provides an overview of chemotherapy-induced hypersensitivity reactions and the evolving strategies for desensitization. Chemotherapy remains the cornerstone in cancer treatment but chemotherapy-related hypersensitivity reactions, including anaphylaxis, pose significant clinical challenges that compromise patient safety in receiving these life-sustaining treatment. The incidence of chemotherapy-associated hypersensitivity reactions is approximately 5 %, with platinum-based agents being the most likely to induce severe reactions. Desensitization protocols have emerged as crucial strategies to mitigate hypersensitivity reactions, enabling patients to safely continue essential chemotherapy. Two primary categories of desensitization exist: rapid drug desensitization and slow drug desensitization. Rapid drug desensitization, which achieves therapeutic doses within 4−12 h, is primarily used for immediate hypersensitivity reactions. Various protocols, including three-bag, twelve-step; four-bag, four-step; and one-bag protocols, have been developed, each with varying efficacy and safety profiles. One bag protocols, which are currently recommended for low risk patients, need to be further evaluated for safety and efficacy before wide implementation. Risk stratification through medical history, skin testing, and drug challenges plays a vital role in determining eligibility for desensitization. Skin testing has proven useful in assessing hypersensitivity, especially to platinum salts. Overall, desensitization has shown to be a generally safe and effective treatment, achieving high completion rates even in cases of breakthrough hypersensitivity.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"6 ","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life efficacy of adjuvant nutraceutical supplement with Boswellia serrata and bromelain for allergic rhinitis","authors":"Cataldo Piarulli ,&nbsp;Stefano Palazzo ,&nbsp;Concetta De Chirico ,&nbsp;Marcello Albanesi","doi":"10.1016/j.jahd.2025.100044","DOIUrl":"10.1016/j.jahd.2025.100044","url":null,"abstract":"","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"6 ","pages":"Article 100044"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144611538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab for atopic children with eosinophilic esophagitis: A case series","authors":"Alireza Maleki ,&nbsp;Stéphanie Willot ,&nbsp;Bertrand Lioger ,&nbsp;Victor Guan-Zhide ,&nbsp;Mélanie Blin ,&nbsp;Anne Hoppe ,&nbsp;Cyrille Hoarau","doi":"10.1016/j.jahd.2025.100034","DOIUrl":"10.1016/j.jahd.2025.100034","url":null,"abstract":"<div><h3>Background</h3><div>The holistic management of atopic diseases and allergic diseases has gained significant relevance with the recent discovery of the role of type 2 inflammation, which links these two entities, and the development of new biotherapies targeting this pathway. Eosinophilic esophagitis is a chronic inflammatory condition of the esophagus. Since eosinophilic esophagitis involves type 2 inflammation through IL-4 and IL-13 pathways, dupilumab offers a promising therapeutic option.</div></div><div><h3>Methods</h3><div>In this case series, we reviewed five pediatric atopic patients, aged between 7 and 17 years, with asthma or atopic dermatitis, who received dupilumab for these conditions and were also affected by eosinophilic esophagitis.</div></div><div><h3>Results</h3><div>We found that dupilumab was effective in all atopic manifestation, including achieving complete clinical, eosinophilic esophagitis endoscopic improvements in all patients and complete histological improvement in 60 % of the patients.</div></div><div><h3>Conclusion</h3><div>Our current study confirms a good efficacy of dupilumab, in the holistic management of atopic young pediatric patients with atopic disease including eosinophilic esophagitis.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"5 ","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic efficacy and safety of topical ruxolitinib in mild-to-moderate atopic dermatitis: A systematic review","authors":"Cintia Bassani ,&nbsp;Gabriel Leite Pértile ,&nbsp;Samuel Luís Scaravonatto Baldo Cunha ,&nbsp;Fernanda de Castro Wordell ,&nbsp;Lara Flavia Gobbi Cazarotto ,&nbsp;Aryani Magalhães Pinheiro Almeida ,&nbsp;Luciana Kase Tanno","doi":"10.1016/j.jahd.2025.100032","DOIUrl":"10.1016/j.jahd.2025.100032","url":null,"abstract":"<div><h3>Objective</h3><div>The objective of this article was to conduct a systematic review of the treatment of light-to-moderate atopic dermatitis by administering topical ruxolitinib.</div></div><div><h3>Methods</h3><div>A comprehensive search was conducted in the online databases Medline, PubMed, SciELO, LILACS, Wanfang, Cochrane Library, Life Science Network, and Embase. Publications from 2019 to October 2024 were selected. The inclusion criteria focused on clinical trials that included both adult and pediatric populations with mild-to-moderate atopic dermatitis, containing control groups. The studies evaluated the efficacy of topical ruxolitinib using standardized outcome measures, such as the Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), and pruritus Numeric Rating Scale (NRS). Studies without control groups, reviews, conference abstracts, case series, and studies on other conditions were excluded. The search used the following keywords: “ruxolitinib” AND “atopic dermatitis”. Duplicate articles on the databases were discarded.</div></div><div><h3>Results</h3><div>The reviewed literature demonstrated that topical ruxolitinib significantly reduces eczema and pruritus in patients with mild-to-moderate atopic dermatitis, showing improvements in EASI, IGA, and NRS scores compared to placebo or conventional treatments. Both adult and pediatric patients tolerated the treatment well, with mild side effects such as nasopharyngitis and upper respiratory tract infections being the most commonly reported adverse events.</div></div><div><h3>Conclusions</h3><div>Topic use of ruxolitinib is very promising for treating atopic dermatitis, demonstrating more effectiveness than conventional therapy.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"5 ","pages":"Article 100032"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143419199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Terms used for hypersensitivity pneumonitis secondary to avian exposures: A scoping review","authors":"Darin Elabbasy ,&nbsp;Timo Clemens ,&nbsp;Natalia Rachwal ,&nbsp;Nivya John ,&nbsp;Hsin-Yi Weng ,&nbsp;Lynette Hart ,&nbsp;Locksley L. McV. Messam","doi":"10.1016/j.jahd.2025.100035","DOIUrl":"10.1016/j.jahd.2025.100035","url":null,"abstract":"<div><h3>Background</h3><div>Hypersensitivity pneumonitis secondary to exposure to avian antigens is referred to in the literature as bird fancier’s lung and numerous other names (hereafter “BFL…”).</div></div><div><h3>Objective</h3><div>This scoping review aims to identify terms used for “BFL…” in the peer-reviewed literature between 1960 and 2021.</div></div><div><h3>Methods</h3><div>We included peer-reviewed articles referring to “BFL…” in humans and published between 1960 and 2021 in English. We searched Medline, Embase, CINAHL, Scopus, and Web of Science, and extracted terms used for “BFL…” along with the year of publication. We categorised the names into occupation-, pathology-, aetiology-, aetio-pathological-, and occupation- and pathology-based terms. We then calculated the total number of terms used, the individual and category-specific frequencies of use for each term, as well as the overall and decade-specific average number of articles to be read in order to encounter a new term.</div></div><div><h3>Results</h3><div>From 3194 initially screened articles, we found 114 terms used for “BFL…” in 1101 articles included for final review. The most frequently used terms were pigeon breeder's disease, bird fancier's lung, hypersensitivity pneumonitis, pigeon breeder's lung and extrinsic allergic alveolitis (in that order), accounting for 65.2 % of terms found. Similarly, occupation-based terms accounted for 67.1 % of terms identified. On average, a new term for “BFL…” was encountered for every 9–10 articles included in the review.</div></div><div><h3>Conclusion</h3><div>The term to b<strong>e</strong> used for “BFL…” should be standardised in the peer-reviewed literature. We suggest “bird fancier lung” be used as the term for hypersensitivity pneumonitis secondary to exposure to avian antigens.</div><div>Clinical Trial Registration: Not applicable.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"5 ","pages":"Article 100035"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-perceived benefits of sublingual allergen immunotherapy: Design of the ERAPP study","authors":"Davide Caimmi ,&nbsp;Abdelilah Abouelfath ,&nbsp;Régis Lassalle ,&nbsp;Séverine Lignot-Maleyran ,&nbsp;Emmanuelle Bignon ,&nbsp;Laure Carcaillon-Bentata ,&nbsp;Patrick Blin ,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2025.100033","DOIUrl":"10.1016/j.jahd.2025.100033","url":null,"abstract":"<div><h3>Introduction</h3><div>Sublingual allergen immunotherapy (SLIT) is an aetiological treatment for allergic disorders (allergic rhinitis, rhinoconjunctivitis, and asthma). Limited data exist on the effectiveness of SLIT in the real-world treatment setting. This study was initiated to assess patient perceptions of the effectiveness of SLIT and thus inform evaluations of its risk−benefit profile in real-world practice. The present article presents the design and methodology of the study and baseline data on the patients enrolled.</div></div><div><h3>Methods</h3><div>This prospective cohort study was performed in patients who were delivered liquid SLIT as a named-patient product in France between September 2020 and February 2022. Participants were stratified by age (&lt; 12 and ≥ 12 years) and by treatment duration. Data were collected through a web-based interface. In the first phase of the study, participants completed study questionnaires at baseline (study entry) and at 6 and 12 to 15 months after inclusion. Perceptions of SLIT were assessed using the Patient Needs Questionnaire and the Patient Benefit Questionnaire. In the second phase of the study, participants’ data will be linked to the French national health data system (SNDS) through their social security number. Data on comorbidities and allergy-related healthcare resource utilisation will be extracted.</div></div><div><h3>Results</h3><div>11,255 patients agreed to participate in the study, of whom 9,439 (83.8 %) could be analysed. 1,837 participants (19.5 %) were children aged &lt; 12 years. 625 participants &lt; 12 years were boys whereas 7,602 older participants were women (58.9 %). 4,974 participants (50.8 %) entered the study within six months of initiating SLIT (new users). Allergic rhinitis was the most frequent allergy presentation (<em>N</em> = 8,291; 87.8 %) and house mite dust the most frequently reported allergen (<em>N</em> = 4,262; 45.1 %).</div></div><div><h3>Discussion</h3><div>This large study including nearly 10,000 participants with allergic disorders should contribute important information for assessing the benefit–risk profile of SLIT.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"5 ","pages":"Article 100033"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A French consensus proposal: Analytical performance targets for total and allergen-specific IgE and total tryptase","authors":"Anne Sarrat ,&nbsp;Joana Vitte ,&nbsp;Yannick Chantran ,&nbsp;Céline Beauvillain ,&nbsp;Marie-Alexandra Alyanakian ,&nbsp;Pol-André Apoil ,&nbsp;Lionel Chollet ,&nbsp;Arnaud Cirée ,&nbsp;Clotilde Amiot ,&nbsp;Erwan Dumontet ,&nbsp;Mylène de Saint-Jore ,&nbsp;Bertrand Evrard ,&nbsp;Lorna Garnier ,&nbsp;Angélique Grenier ,&nbsp;Valérie Guérin-El Khourouj ,&nbsp;Caroline Hémont ,&nbsp;Anthony Léon ,&nbsp;Delphine Mariotte ,&nbsp;Moïse Michel ,&nbsp;Pascale Nicaise-Roland ,&nbsp;Julien Goret","doi":"10.1016/j.jahd.2025.100037","DOIUrl":"10.1016/j.jahd.2025.100037","url":null,"abstract":"<div><div>Precision medicine allows thorough characterization of patients endotype in allergy and anaphylaxis, thanks to progress in diagnostic tests and biomarkers. Allergy tests must therefore offer reliable, robust, and proficient quantitative results in each patient. These requirements have led to the development of quality assurance programs for allergy laboratory assays and their implementation in virtually all clinical laboratories performing in vitro allergy diagnosis and follow-up. However, consensus analytical performance targets for allergy assays have not yet been established. Here, the multicentric French network of public clinical laboratories and the Working Group on in vitro allergy diagnosis of the French Society of Allergy define performance criteria for specific and total IgE and tryptase tests.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"5 ","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}